Official Title A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)

Purpose

The purpose of this study is to evaluate the efficacy of ESK-001 

There may be a chance that you will be asked to come into the study site for unscheduled study visits that may include extra tests to assess for your safety.

The duration of the study will be a minimum of 28 weeks, if you participate in the long-term extension study, or 32 weeks if instead you enter the follow-up period. You will need to come to the study site at least 10 or 11 times respectively over this period. 

Could this study be right for you?

• Subject must have a diagnosis of plaque psoriasis for at least 6 months 
• Subjects must not have other immune-mediated conditions such as uveitis and inflammatory bowel disease (patients with psoriatic arthritis may participate) 
• Subject must be in good general health with no history of tuberculosis, cancer, HIV, hepatitis B or C
• Subjects must have no history of unstable cardiac disease (for example, unstable angina or rapid atrial fibrillation) or cardiac hospitalization within 3 months 
• Female subjects must not be pregnant or considering becoming pregnant for the duration of the study 

Age Range

18 years and up

Official Title A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa

Purpose

The purpose of this study is to evaluate the efficacy of lutikizumab

Could this study be right for you?

• Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
• Subject must have tried a 12-week (about 3 months) trial of oral antibiotics with inadequate improvement
• Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
• Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study

Age Range

18 years and up

Official Title A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Adaptive Phase III Trial To Investigate Efficacy And Safety Of Viobelimab In The Treatment Of Ulcerative Pyoderma Gangrenosum

Purpose

This study aims to find out if a new investigational drug, vilobelimab (also called IFX-1) is safe and effective in treating pyoderma gangrenosum. 

The study will measure if the study drug closes the ulcers of your skin. It will also measure if the study drug improves the severity of your disease (according to the study doctor and according to you) and if it improves your pain and your quality of life. 

Could this study be right for you?

• Investigator confirmed clinical diagnosis of ulcerative pyoderma gangrenosum (PG). 

• Minimum of 1 PG ulcer (other than peristomal) which qualifies as the target ulcer 

  • Area of at least 5 cm2 at screening and baseline  
  • Circulated by intact skin  
  • Evaluable by at least 2-dimensional measurement 

Age Range

18 years and up

Official Title A Randomized, Double-Blind, Multi-Center Comparative Effectiveness Study Of Spironolactone Versus Doxycycline Hyclate For The Treatment Of Acne In Women

Purpose

To determine whether spironolactone is non-inferior to the oral tetracycline-class antibiotic doxycycline hyclate in the treatment of acne in women 

Could this study be right for you?

• Assigned female at birth  

• Acne defined as at least 10 inflammatory papules or pustules 

• Not currently pregnant or planning to become pregnant  

• Willing to attest to abstinence or some form of contraception for the duration of the study (4 months). Approved options of birth control to use during the study include:  

  • Hormonal contraception (for example, birth control pills, injection, implant, transdermal patch, vaginal ring)  
  • Intrauterine device (IUD)  
  • Tubal ligation (tying your tubes)  
  • Partner with a vasectomy  
  • Male or female condom with spermicide  
  • Diaphragm with spermicide  
  • Cervical cap contraceptive sponge with spermicide  

Age Range

16 - 40 years

Official Title A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients

Purpose

The purpose of this study is to evaluate the efficacy of minoxidil.

Could this study be right for you?

• Subjects must have a diagnosis of breast cancer stages I-IV
• Subjects must have hair loss while on endocrine therapy (i.e., tamoxifen or an aromatase inhibitor such as anastrozole)
• Subjects must not be on chemotherapy or have been on chemotherapy within 2 years
• Subjects must not have tried oral or topical minoxidil or spironolactone previously
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study

Age Range

18 - 70 years

Official Title A Multicenter Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy

Purpose

• Subject must have a diagnosis of cutaneous lupus erythematosus 

• Subject must have tried antimalarial treatment (i.e., hydroxychloroquine, quinacrine, or chloroquine) for at least 12 weeks (about 3 months) or was unable to tolerate antimalarial treatment due to side effects 

• Subject must be in good general health with no history of tuberculosis, cancer, HIV, or hepatitis B or C 

• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study 

Could this study be right for you?

• Subject must have a diagnosis of cutaneous lupus erythematosus
• Subject must have tried antimalarial treatment (i.e., hydroxychloroquine, quinacrine, or chloroquine) for at least 12 weeks (about 3 months) or was unable to tolerate antimalarial treatment due to side effects
• Subject must be in good general health with no history of tuberculosis, cancer, HIV, or hepatitis B or C
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study

Age Range

18 - 70 years